Literature DB >> 8162607

A novel approach to estimate the proportion of hereditary nonpolyposis colorectal cancer of total colorectal cancer burden.

L A Aaltonen1, R Sankila, J P Mecklin, H Järvinen, E Pukkala, P Peltomäki, A de la Chapelle.   

Abstract

The incidence of hereditary nonpolyposis colorectal cancer (HNPCC) is not precisely known. Common estimates are 4 to 6% of all colorectal cancers (CRCs), but lower figures have been published. In an attempt to obtain an independent new estimate of this proportion and to identify more HNPCC families, we designed a new method. Based on the fact that age at diagnosis is considerably lower in hereditary than in sporadic CRC, a cohort of 227 CRC patients aged 44 years or younger diagnosed during the years 1985-1989 and reported to the Finnish Cancer Registry was chosen as probands. Pedigrees of the probands were constructed by combining information from the Finnish Population Register Center and Finnish Cancer Registry using only automatically processed data. Sixteen pedigrees were extended further by the help of parish registers. Six of these turned out to be new possible HNPCC families but none met the stringent criteria of the cancer syndrome. Our results can be interpreted to suggest that the proportion of HNPCC of all CRCs is between 0.5 and 0.9%, depending on the diagnostic criteria used. Modifications of our method should be useful in other research projects dealing with diseases in which a subset is due to genetically or environmentally determined susceptibility.

Entities:  

Mesh:

Year:  1994        PMID: 8162607

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  24 in total

1.  Determining the frequency of de novo germline mutations in DNA mismatch repair genes.

Authors:  Aung Ko Win; Mark A Jenkins; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Graham G Giles; Jack Goldblatt; Barbara A Leggett; John L Hopper; Stephen N Thibodeau; Noralane M Lindor
Journal:  J Med Genet       Date:  2011-06-02       Impact factor: 6.318

2.  Lower prevalence of Lynch syndrome in colorectal cancer patients in a Japanese hospital-based population.

Authors:  Kensuke Kumamoto; Hideyuki Ishida; Okihide Suzuki; Yusuke Tajima; Noriyasu Chika; Koki Kuwabara; Keiichiro Ishibashi; Katsuharu Saito; Koji Nagata; Hidetaka Eguchi; Junichi Tamaru; Takeo Iwama
Journal:  Surg Today       Date:  2015-08-07       Impact factor: 2.549

3.  The importance of older family members in providing social resources and promoting cancer screening in families with a hereditary cancer syndrome.

Authors:  Sato Ashida; Donald W Hadley; Andrea F Goergen; Kaley F Skapinsky; Hillary C Devlin; Laura M Koehly
Journal:  Gerontologist       Date:  2011-05-11

4.  Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer.

Authors:  A L Moisio; P Sistonen; J Weissenbach; A de la Chapelle; P Peltomäki
Journal:  Am J Hum Genet       Date:  1996-12       Impact factor: 11.025

Review 5.  Genetic susceptibility to non-polyposis colorectal cancer.

Authors:  H T Lynch; A de la Chapelle
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

Review 6.  The incidence of Lynch syndrome.

Authors:  Albert de la Chapelle
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

7.  Accuracy of MSI testing in predicting germline mutations of MSH2 and MLH1: a case study in Bayesian meta-analysis of diagnostic tests without a gold standard.

Authors:  Sining Chen; Patrice Watson; Giovanni Parmigiani
Journal:  Biostatistics       Date:  2005-04-14       Impact factor: 5.899

8.  Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.

Authors:  Driss Ait Ouakrim; Seyedeh Ghazaleh Dashti; Rowena Chau; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Joanne P Young; Graham G Giles; Barbara Leggett; Finlay A Macrae; Dennis J Ahnen; Graham Casey; Steven Gallinger; Robert W Haile; Loïc Le Marchand; Stephen N Thibodeau; Noralane M Lindor; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  J Natl Cancer Inst       Date:  2015-06-24       Impact factor: 13.506

9.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

10.  Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome.

Authors:  Rowena Chau; Seyedeh Ghazaleh Dashti; Driss Ait Ouakrim; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Joanne P Young; Graham G Giles; Finlay A Macrae; Alex Boussioutas; Susan Parry; Jane C Figueiredo; A Joan Levine; Dennis J Ahnen; Graham Casey; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Stephen N Thibodeau; Noralane M Lindor; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  Int J Epidemiol       Date:  2016-04-10       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.